CONCLUSION

In conclusion, prevention and control measures for the outbreak of COVID-19 have postponed the diagnosis and treatment of patients with NPC, which may affect the prognosis of patients to a certain extent, or increase unnecessary treatment intensity of patients. Timely and effective treatment for patients with high-risk recurrence under the controlling measure of the COVID-19 was needed so as to ensure the efficacy of these patients. And we call for the introduction of guidance related to the diagnosis and treatment of NPC with more detailed supervision to deal with the impact of COVID-19 control measures. It is worth noting the efficacy of patients during the epidemic period with long-term follow-up.

Ethics and Consent Statements

This study was approved by the Ethical Committee and Institutional Review Board of Fudan University Shanghai Cancer Centre (FDUSCC). The method was based on approved guidelines. Informed consent was written by all participants.


Continue Reading

Acknowledgments

We thank all the patients who consented to the study and the anonymous reviewers for their helpful comments.

Disclosure

The authors report no conflicts of interest in this work.


Youqi Yang, Chunying Shen, Chaosu Hu
Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Shanghai 200032, People’s Republic of China
Correspondence: Chaosu Hu No. 270, Dong’an Road, Shanghai, People’s Republic of China
Tel Fax + 8602164175590
Email [email protected]


References

1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa2001017

2. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi:10.1056/NEJMoa2002032

3. Stoker SD, Wildeman MA, Fles R, et al. A prospective study: current problems in radiotherapy for nasopharyngeal carcinoma in yogyakarta, indonesia. PLoS One. 2014;9(1):e85959. doi:10.1371/journal.pone.0085959

4. Liang H, Xiang YQ, Lv X, et al. Survival impact of waiting time for radical radiotherapy in nasopharyngeal carcinoma: A large institution-based cohort study from an endemic area. Eur J Cancer. 2017;73:48–60. doi:10.1016/j.ejca.2016.12.009

5. Chen YP, Mao YP, Zhang WN, et al. Prognostic value of wait time in nasopharyngeal carcinoma treated with intensity modulated radiotherapy: a propensity matched analysis. Oncotarget. 2016;7(12):14973–14982. doi:10.18632/oncotarget.7789

6. Stoker SD, Fles R, Herdini C, et al. The impact of the overall radiotherapy time on clinical outcome of patients with nasopharyngeal carcinoma; a retrospective study. PLoS One. 2016;11(3):e0151899. doi:10.1371/journal.pone.0151899

7. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55:105924. doi:10.1016/j.ijantimicag.2020.105924

8. Sheng L, Shui Y, Shen L, Wei Q. Effect of patient-related delay in diagnosis on the extent of disease and prognosis in nasopharyngeal carcinoma. Am J Rhinol. 2008;22(3):317–320. doi:10.2500/ajr.2008.22.3174

9. You R, Sun R, Hua YJ, et al. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma. Int J Cancer. 2017;141(6):1265–1276. doi:10.1002/ijc.30819

10. Tang LQ, Chen DP, Guo L, et al. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: an open-label, non-inferiority, randomised Phase 3 trial. Lancet Oncol. 2018;19(4):461–473. doi:10.1016/S1470-2045(18)30104-9

11. Liu SL, Sun XS, Yan JJ, et al. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response. Radiother Oncol. 2019;137:83–94. doi:10.1016/j.radonc.2019.04.020

12. Ou X, Zhou X, Shi Q, et al. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost. Oncotarget. 2015;6(35):38381–38397. doi:10.18632/oncotarget.5420

13. Wei Z, Zhang Z, Luo J, Li N, Peng X. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study. J Cancer Res Clin Oncol. 2019;145(7):1857–1864. doi:10.1007/s00432-019-02925-z

14. Chen X, Zhu X, Wang J, Liu J, Ji R. NACT+IMRT versus NACT+IMRT+CCRT in locoregionally advanced NPC patients: a retrospective study. Onco Targets Ther. 2019;12:1553–1562. doi:10.2147/OTT.S183483

15. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335–337. doi:10.1016/S1470-2045(20)30096-6

Source: Cancer Management and Research.
Originally published May 7, 2020.

READ FULL ARTICLE Curated publisher From Dovepress